"CHICAGO, May 20 (Reuters) - An experimental colorectal cancer drug being developed by Keryx Biopharmaceuticals (KERX) showed it improved overall survival and slowed cancer progression in patients with advanced colorectal cancer, according to a summary of final data from a mid-stage study.
Researchers said the drug KRX-0401, also known as perifosine, was well tolerated and showed "promising activity" over chemotherapy as a second or third-choice drug for patients with colorectal cancer that has spread.
The drug, being developed jointly with Canadian drugmaker Aeterna Zentaris (AEZS), blocks the activation of Akt, a new pathway thought to be linked with cell death and survival.
High levels of activated Akt are seen frequently in many types of cancer, and are often a sign of poor prognosis.
Last month, U.S. regulators granted the drug fast-track approval, a designation that speeds the regulatory approval process."
I looked at the data: they are GOOD. This is big stuff. Both stocks lost some value recently.
